Bausch Health Companies Inc (NYSE:BHC) shares traded up 0.5% during mid-day trading on Tuesday . The company traded as high as $23.08 and last traded at $22.48. 165,100 shares were traded during mid-day trading, a decline of 98% from the average session volume of 6,630,510 shares. The stock had previously closed at $22.36.
A number of research analysts have issued reports on the company. HC Wainwright set a $25.00 price target on Bausch Health Companies and gave the company a “hold” rating in a report on Monday, October 15th. Zacks Investment Research downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. TD Securities boosted their price target on Bausch Health Companies from $24.00 to $28.00 and gave the company a “hold” rating in a report on Wednesday, November 7th. ValuEngine raised Bausch Health Companies from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Finally, Deutsche Bank set a $30.00 price target on Bausch Health Companies and gave the company a “buy” rating in a report on Wednesday, September 12th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $26.73.
The company has a quick ratio of 0.91, a current ratio of 1.14 and a debt-to-equity ratio of 7.55. The company has a market capitalization of $7.43 billion, a price-to-earnings ratio of 6.09, a P/E/G ratio of 0.28 and a beta of 0.14.
Bausch Health Companies (NYSE:BHC) last announced its earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.31. The business had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.09 billion. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. Bausch Health Companies’s revenue was down 3.7% on a year-over-year basis. Research analysts predict that Bausch Health Companies Inc will post 3.81 EPS for the current year.
In related news, EVP Christina Ackermann sold 19,946 shares of the stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total value of $498,251.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas Appio acquired 25,440 shares of Bausch Health Companies stock in a transaction that occurred on Friday, December 14th. The stock was purchased at an average cost of $22.96 per share, with a total value of $584,102.40. The disclosure for this purchase can be found here. Corporate insiders own 11.54% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of BHC. Private Management Group Inc. acquired a new position in Bausch Health Companies in the 2nd quarter valued at $28,474,000. Marshall Wace LLP acquired a new position in Bausch Health Companies in the 2nd quarter valued at $2,974,000. NEXT Financial Group Inc acquired a new position in Bausch Health Companies in the 3rd quarter valued at $101,000. Montrusco Bolton Investments Inc. acquired a new position in Bausch Health Companies in the 3rd quarter valued at $4,768,000. Finally, Nexus Investment Management Inc. purchased a new stake in Bausch Health Companies in the 3rd quarter valued at $862,000. 50.09% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was published by Zolmax and is the sole property of of Zolmax. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://zolmax.com/investing/bausch-health-companies-bhc-trading-0-5-higher/2816116.html.
Bausch Health Companies Company Profile (NYSE:BHC)
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.